Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Luminice-203 yields its first topline data, but where are all the patients?
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Pfizer moves to take PF-07934040 into its first clinical trial.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.